48 results about "Screening cancer" patented technology

The invention relates to methods and products for treating cancer. In particular the invention relates to combinations of nucleic acids and antibodies for the treatment and prevention of cancer. The invention also relates to diagnostic methods for screening cancer cells.

The invention relates to a cell surface receptor biochip based on a surface plasmon resonance biosensor, a preparation method and application thereof. The biochip is characterized in that the chip is provided with a gold surface coating at a glass substrate and the gold surface is fixed with a sephadex layer which is fixed with the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin and surface receptors are fixed by antibody capture. The preparation method includes that the monoclonal antibody of the Beta subunit of the receptors of anti para-insulin adopts the method of antibody capture and is fixed on the surface of CM5 chip based on the surface plasmon resonance biosensor, so as to produce the protein chip of para-insulin receptors which is applicable to the mutual action between IGF-1R and IRS-1, SHC, PI3K or GRB2 and hopeful to be applied to screening cancer-fighting drugs.

It is intended to provide a method of improving dietary life or screening cancer which comprises measuring the content of an element in head hair or body hair, paying attention to the fact that the content of the element remains constant in healthy humans (i.e., homeostasis) and thus evaluating the physical conditions based on changes in the homeostasis. Namely, a method of evaluating the physical conditions whereby the physical conditions can be evaluated by measuring the content of an element in an arbitrary part of head hair or body hair. Although one's physical conditions change everyday, these changes are scarcely self-noticeable. Therefore, it is required to objectively indicate such changes in the physical conditions in numerical terms. Because of being solid, head hair or body hair can be easily handled. Thus, they are most suitable for analyzing the content of an element and enable large-scaled diagnosis at fixed intervals. This method of evaluating the physical conditions using head hair or body hair, whereby the content of an element at present can be measured by analyzing the hair root while its content of the past can be measured by analyzing at an arbitrary part, is highly effective in evaluating the physical conditions.

The invention relates to a targeting qualitative and quantitative metabonomic technical analysis method used for screening cancer biomarkers based on the LC-MS/MS technology. The method is characterized in that a structure prediction function of multi-reaction monitoring-dependent information acquisition-enhanced daughter ion detection on correlative metabolites and a structure identification function of a high-resolution mass spectrum are predicted by fully utilizing a multi-reaction monitoring quantitation function of the high performance liquid-tandem mass spectrum, and the analysis methodsuitable for screening biomarkers of various cancers is formed. The method has the advantages of high flux, good stability and high adaptability, and improves sensitivity and accuracy of screening andfinding of metabonomic biomarkers.

The invention discloses an intelligent cervical cancer cell detection method based on deep learning. The invention relates to classification of cell nucleuses by a deep learning method. The inventionaims to solve the problems of low cancer cell detection accuracy, long consumed time and the like in the existing traditional diagnosis mode. In order to solve the problem, the invention provides an intelligent cervical cancer cell screening method based on deep learning. The method comprises the following specific steps: 1, preparing data; 2, carrying out cell nucleus segmentation; 3, carrying out cell nucleus classification; and 4, screening cancer cells. In the cell nucleus classification part, data expansion and category subdivision are carried out on the data by using an active learning method; on the model, ResNeSt is taken as a basic model, doctor diagnosis experience is introduced, and a more accurate model is trained under the combined action of diagnosis index extraction. Experiments show that the accuracy of the cell nucleus classification method is higher than that of an original model, and in addition, the invention further provides a more effective data preparation methodfor expanding data and subdividing categories. The method is applied to the field of medical image classification.

Monospecific polyclonal fibrinogen degradation product antibodies, their method of use, the methods to detect cancer and for monitoring the progress of anticancer treatment by immunochemically measuring the quantity of serum FDP in serum are disclosed. The present invention teaches that monospecific polyclonal FDP antibodies that bind to human fibrinogen degradation products (“FDP”) can be obtained by inoculating a laboratory animal with human FDP or human FDP derivatives to induce the production in the inoculated laboratory animal of at least one monospecific polyclonal antibody that binds to human FDP and isolating the monospecific polyclonal antibody. By generating anti-serum to FDP from immunogens and purifying said immunogens using affinity chromatography, increased levels of production of FDP antibodies over the prior art are achieved. A method for screening cancer is disclosed comprising contacting biological sample obtained from a patient with at least one monospecific polyclonal FDP antibody that binds to mammalian FDP. A method is also disclosed for producing a quantitative enzyme linked immunosorbent assay (ELISA) for serum FDP by using monospecific polyclonal antibodies that bind to human FDP.

The invention discloses a method for detecting telomerase activity in liquid biopsy, which utilizes avidin-labeled magnetic beads to adsorb and label the extended product with biotin after screening cancer cells, thereby achieving the effect of removing proteins and other impurities in the liquid. Compared with the prior art, the invention has the advantages that: At that end of screen cancer cell, 1*TRAP system, biotin-labeled TS primer, dNTP, RII were added. After the cells were disrupted by ultrasound, the telomerase activity was elongated by 30 DEG C water bath for 30 minutes, and then magnetic beads were added to remove the liquid. Finally, tRAP PCR reaction system was added to carry out PCR reaction with magnetic beads. This method can completely remove the influence of protein and other impurities, and the magnetic beads labeled with avidin have super affinity with the target product labeled with biotin, which can ensure the efficiency of extraction.

The invention discloses a cancer screening and diagnosis method via staining quantification of cellular DNA by a fluorescent dye DAPI. According to the method, cell nucleuses in cell smears or cells and tissue sections are stained with DAPI as a dye, pictures are taken under a fluorescence microscope, and the DNA in each nucleus is relatively quantified according to the fluorescence intensity of each nucleus. Cells with abnormal DNA content (non-integer ploidy or ploidy number being greater than 4.5 or above) are suspected cancer cells. The number and morphology of the suspected cancer cells can be used for cancer screening and diagnosis. The dyeing method provided by the invention has the advantages of short dyeing time, simple operation and accurate quantification, is wide in application, can quantify the DNA of cells in cell smears, tissue sections and cultured cells, and can be used for screening cancer samples.

Provided in the present invention are a molecule for biomarking cancers and a test composition for screening cancers and a detection method thereof comprising designing a number of oligonucleotide primers or probes by analyzing specimens for methylated regions of targeted genes PAX1, ZNF582, SOX1 and NKX6-1 in physical examination, and then using the oligonucleotide probes to detect whether methylation exists in the target genes, and further judge the likelihood of the occurrence of cancer. The detection methods for methylation status include methylation-specific PCR, (MSP), quantitative methylation-specific PCR (QMSP), bisulfate sequencing (BS), microarrays, mass spectrometer, denaturing high-performance liquid chromatography (DHPLC), pyrosequencing, and enzyme-linked immunosorbent assay (ELISA).

A method of classifying a patient for eligibility for cancer therapy based on the presence or absence of splicing variants in a sample of the patient's cancer tissue. Also, a method of screening cancer therapies for efficacy against splicing variants. More specifically, the methods relate to novel splicing variants of genes associated with cancer risk and survival, particularly splicing variants of PIK3CD, FGFR3, TSC2, RASGRP2, ITGA4, MET, NF1 and BAK1. Also more specifically, the methods relate to classifying a patient for eligibility for cancer therapy involving the use of GS-1101.

The present invention relates to a composition for diagnosing cancer metastasis comprising Ubiquitin C-terminal hydrolase-L1 (UCH-L1), a use of UCH-L1 for diagnosing cancer metastasis and a method for diagnosing cancer metastasis using the same; a composition for suppressing cancer metastasis comprising an inhibitor of UCH-L1, a use of an inhibitor of UCH-L1 for suppressing cancer metastasis and a method of suppressing cancer metastasis using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 protein, a use of UCH-L1 protein for screening a cancer metastasis inhibitor and a method of screening cancer metastasis inhibitor using the same; a composition for screening a cancer metastasis inhibitor comprising UCH-L1 gene, a use of UCH-L1 gene for screening a cancer metastasis inhibitor, a method of screening cancer metastasis inhibitor using the same.

UCH-L1 is a key molecule to modulate cell migration including the cancer invasion according to their expressing level. Thus, the monoclonal and polyclonal antibodies and the substrate of UCH-L1 can be used for diagnosis of cancer metastasis.

Also, the cancer metastasis can be suppressed by inhibiting of the expression of UCH-L1 or activity of the enzyme, thus we can screen and develop an inhibitor of UCH-L1 and use it as an adjuvant drug for anticancer therapy.

The invention provides an identification technology of a novel circulating tumor cell (CTC). The identification technology is used for identifying the CTC. The method is characterized in that body fluid (such as peripheral blood) of a tumor patient is subjected to standard sampling, transportation and storage, sample pretreatment, CTC enrichment and separation on a microfiltration film, cell immobilization, cell silver staining and immunofluorescence in-situ detection, whether the cells are tumor cells or not is determined according to the karyoplasm proportion, the irregular nucleolus characteristics and the number, and finally the organ tissue source of CTC in blood is determined through fluorescence immunoassay of tissue and organ specific protein markers. According to the method, CTC is subjected to in-situ microscopic examination, tumor cells are detected, organ tissue sources of circulating tumor cells are determined, a long-term problem that CTC morphological identification lacks a believable method is solved, and establishment of a unified standard for CTC detection is facilitated. The method has advantages of being easy to operate, good in repeatability, high in stabilityand the like, and can be used for early screening of tumor high-risk groups, curative effect evaluation of cancer patients and recurrence monitoring.

The present invention relates to a method for screening an anticancer agent or a cancer preventive agent, comprising the steps of: (a) isolating mutant luterial or normal luterial from a body fluid extracted from a patient or a normal person; (b) treating the isolated mutant luterial with anticancer agent candidates or cancer preventive agent candidates; and (c) either selecting, as the anticancer agent, a candidate that reduces the size or changes the shape or increases the mobility of the mutant luterial, compared to the control mutant luterial upon treatment with the candidate, or selecting, as the cancer preventive agent, a candidate that suppresses the increase in size, minimizes the change in shape or maintains the mobility of luterial, compared to the control luterial, upon treatment with the candidate.

The invention relates to a single cell transcriptome sequencing (scRNA-seq) technology which is applied to primary cells or cell lines for high-throughput drug screening and new application of old drugs. The present invention relates to an analytical method for cell-based drug screening, comprising the steps of: culturing a population of cells in a culture environment; exposing the cell population to a drug substance, wherein a clear time monitoring point and a concentration monitoring point of the drug substance are set; after being exposed in a drug substance, a single cell library is formed; performing single-cell RNA sequencing of the single-cell library on a plurality of genes of the independently sorted cells in the cell library; and performing a bioinformatics analysis to determine differentially expressed genes. Furthermore, the present invention relates to the use of an analytical method for cell-based drug screening in which differentially expressed genes are potential marker genes and are used for screening cancer drugs.

The invention provides a cancer marker screening method, which comprises the following steps: screening cancer markers based on tissue gene expression level differences between a target cancer and other cancers, and tissue gene expression level differences and methylation level differences between the target cancer and normal tissues, wherein the gene expression level difference between the target cancer and other cancer tissues indicates that the gene expression level of the marker in the target cancer is obviously higher than that of the marker in other cancer tissues, the gene expression level difference between the target cancer and the normal tissue indicates that the gene expression level of the marker in the target cancer is obviously higher than that in the normal tissue, and the methylation level difference between the target cancer and the normal tissue indicates that the methylation level of the marker in the target cancer is obviously higher than that of the marker in the normal tissue. The method disclosed by the invention is expected to be complementary with a conventional methylation marker, well improves the cancer detection rate, and has the advantages of accuracy, rapidness and high throughput.